Secukinumab (cubana) is a recombinant, high-affinity, fully human monoclonal antibody immunoglobulin G1κ selectively binds and neutralizes That interleukin-17A. To confirm the findings of basic research and early clinical studies Regarding the crucial role of interleukin-17A in psoriasis, we Conducted two randomized, phase trials to ASSESS the efficacy and safety of secukinumab, at a dose of 300 mg or 150 mg, administered as induction therapy (with assessment at week 12) and maintenance therapy (with assessment at week 52) in Patients With moderate-to-severe plaque psoriasis. (Efficacy of Response and Safety of Two Fixed Secukinumab regimens in Psoriasis) study secukinumab Compared With placebo, and the ( Examination of Secukinumab vs. Etanercept Using Two Dosing regimens to Determine Efficacy in Psoriasis) study secukinumab Compared With Placebo and, the tumor necrosis factor first (TNF) inhibitor approved by the for moderate-to-severe plaque psoriasis
Substance P is the first neuroactive substance that is proposed as a neurotransmitter. As for the pharmacological properties of substance P, they were demonstrated to check exhibiting potent hypotensive properties that were not blocked by atropine. He was later identified as the first active neuropeptide and was proposed as a neurotransmitter. In the 70s the structure is now known to contain eleven amino acids, of which six corresponding to the C-terminus are essential for its biological activity was determined. Substance P (SP) is a neuropeptide of eleven amino acids, are much smaller than other neurotransmitters amounts, is synthesized in the cell body and transported along the axon to the terminals, it is synthesized as part of a prepropeptide ( preproteins or precursors) of higher molecular weight which then moves to the cisterns of the endoplasmic reticulum, where it is disintegrated to produce a proprotein. The proprotein is transported to the Golgi apparatus, where they may fac...
Comentarios